John C. Molina
YOU?
Author Swipe
View article: From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL
From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL Open
View article: Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia
Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia Open
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event‐free…
View article: Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients with Acute Lymphoblastic Leukemia at a Tertiary Center
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients with Acute Lymphoblastic Leukemia at a Tertiary Center Open
View article: <i>JAK2</i> p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms
<i>JAK2</i> p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms Open
The Janus kinase 2 (JAK2) V617F mutation activates the transcription pathway and has been well characterized as a driver of myeloproliferative neoplasms (MPNs). Recently, there has been a heightened interest in understanding germ line pred…
View article: Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients
Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients Open
View article: Acute lymphoblastic leukemia in young adults: which up-front treatment?
Acute lymphoblastic leukemia in young adults: which up-front treatment? Open
Significant improvements have occurred for adolescent and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients following the widespread adoption of “pediatric-inspired” treatment regimens for AYA patients cared for in adu…
View article: Gaps in Adolescent and Young Adult Cancer Education in Oncology Fellowship Training
Gaps in Adolescent and Young Adult Cancer Education in Oncology Fellowship Training Open
Purpose: Adolescents and young adults (AYAs, 15-39 years) with cancer experience disparities in care and outcomes compared with older/younger patients. AYAs receive care from medical and pediatric oncologists, however, little…
View article: Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives
Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives Open
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powe…
View article: Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy
Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy Open
Background An adequate absolute lymphocyte count (ALC) is an essential first step in autologous chimeric antigen receptor (CAR) T‐cell manufacturing. For patients with acute myelogenous leukemia (AML), the intensity of chemotherapy receive…
View article: CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR Open
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B…
View article: Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation Open
Chimeric antigen receptor T-cells (CART) are active in relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), but relapse remains a substantial challenge. Reinfusion with the same CART product (CART2) in patients with subop…
View article: Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy Open
Chimeric antigen receptor (CAR) T cells effectively eradicate medullary B-cell acute lymphoblastic leukemia (B-ALL) and can traffic to and clear central nervous system (CNS) involvement. CAR T-cell activity in non-CNS extramedullary diseas…
View article: Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation
Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation Open
View article: Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days Open
Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to evolve, infection risks and management thereof will become …
View article: CAR T cells better than BiTEs
CAR T cells better than BiTEs Open
This article has a companion Counterpoint
View article: Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia
Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia Open
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome (MDS)/myeloproliferative disorder most commonly seen in the elderly. We describe an adolescent with monosomy 7 CMML presenting as central diabetes insipidus (DI), who was…